AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
MONDAY, May 1, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free survival (EFS), according to a study presented at the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Pharmaceuticals | Study